251 related articles for article (PubMed ID: 26756205)
1. Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.
Raman F; Scribner E; Saut O; Wenger C; Colin T; Fathallah-Shaykh HM
PLoS One; 2016; 11(1):e0146617. PubMed ID: 26756205
[TBL] [Abstract][Full Text] [Related]
2. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth.
Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM
Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139
[TBL] [Abstract][Full Text] [Related]
3. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
4. Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary.
Scribner E; Fathallah-Shaykh HM
PLoS One; 2017; 12(1):e0169434. PubMed ID: 28046101
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression and treatment effect.
Jahangiri A; Aghi MK
Neurosurg Clin N Am; 2012 Apr; 23(2):277-87, viii-ix. PubMed ID: 22440871
[TBL] [Abstract][Full Text] [Related]
6. Image-driven modeling of the proliferation and necrosis of glioblastoma multiforme.
Patel V; Hathout L
Theor Biol Med Model; 2017 May; 14(1):10. PubMed ID: 28464925
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.
Velpula KK; Bhasin A; Asuthkar S; Tsung AJ
Cancer Res; 2013 Dec; 73(24):7277-89. PubMed ID: 24148623
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
9. Invasion as target for therapy of glioblastoma multiforme.
Vehlow A; Cordes N
Biochim Biophys Acta; 2013 Dec; 1836(2):236-44. PubMed ID: 23891970
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic Chemotherapy to Abrogate Glioblastoma Multiforme Migration/Invasion.
Helson L; Majeed M
Anticancer Res; 2019 Jul; 39(7):3423-3427. PubMed ID: 31262865
[TBL] [Abstract][Full Text] [Related]
12. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
Miekus K; Kijowski J; Sekuła M; Majka M
Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
[TBL] [Abstract][Full Text] [Related]
13. [GLIOBLASTOMA MULTIFORME--THE PROGRESS OF KNOWLEDGE ON THE PATHOGENESIS OF CANCER].
Wańkowicz P; Nowacki P
Ann Acad Med Stetin; 2014; 60(2):40-3. PubMed ID: 26591106
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
15. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
16. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
Bambury RM; Morris PG
Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
[TBL] [Abstract][Full Text] [Related]
17. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy.
Grunnet ML; O'Neill A; Gilbert M; Hellman R
Clin Neuropathol; 2000; 19(5):230-4. PubMed ID: 11048748
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
19. Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.
Scribner E; Saut O; Province P; Bag A; Colin T; Fathallah-Shaykh HM
PLoS One; 2014; 9(12):e115018. PubMed ID: 25506702
[TBL] [Abstract][Full Text] [Related]
20. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
